Awardee OrganizationRUTGERS, THE STATE UNIV OF N.J.
Description
Abstract Text
DESCRIPTION (provided by applicant): Ribosome inactivating proteins (RIPs) have been used as instruments of biological warfare and terrorism. Ricin is a heterodimeric plant toxin that consists of A and B-chains and the prototype of type II RIPs. Its B- chain is a lectin that enables cell binding. After endocytosis, the A-chain translocates through the endoplasmic reticulum membrane to reach the cytosol where its N-glycosidase activity removes a specific adenine from the highly conserved, sarcin/ricin loop (SRL) in the large rRNA. Ricin has been classified as Category B priority for biodefense. Very little is known about the membrane translocation and ribosome interactions of ricin and the molecular mechanism by which it causes apoptosis in mammalian cells. We have established yeast as a biologically relevant model system to study the activity of RTA, and isolated mutant forms of RTA, which do not kill cells. Translation inhibition by ribosome depurination has been hypothesized to be responsible for the cytotoxicity of ricin. However, our preliminary analysis of the nontoxic RTA mutants indicates that ribosome depurination is not sufficient for cytotoxicity. This project aims to use yeast and mammalian cells as complementary systems to understand the molecular basis for ricin intoxication. Specific Aims: 1. Using the nontoxic RTA mutants, determine if ribosome binding and depurination are required for cytotoxicity in yeast and induction of apoptosis in mammalian cells. 2. Characterize the interaction between RTA and ribosomal protein PO and determine if binding to PO is essential for ribosome depurination by RTA. 3. Identify the cellular genes necessary for cytotoxicity of RTA in yeast and determine if RTA causes cell death by affecting induction of the unfolded protein response (UPR). Ricin is not only a bioterrorism threat, but inhibits translation by a similar mechanism as the bacterial enterotoxins. Therefore, the studies outlined in this application will have important implications for the design of protection strategies against AB-toxins that are classified as high-risk candidates for bioterrorism.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAdenineAerosolsAffectAntidotesApoptosisApoptoticBindingBiochemicalBiological ModelsBiological WarfareBioterrorismBreathingCategoriesCell DeathCellsCessation of lifeCytosolDefectDepurinationDevelopmentEndocytosisEndoplasmic ReticulumEnterotoxinsGenesGenomeGenomicsInduction of ApoptosisIntoxicationLectinLungMAPK14 geneMAPK8 geneMammalian CellMeasuresMedicalMembraneMessenger RNAMolecularMutagenesisN glycosidaseNational Institute of Allergy and Infectious DiseasePlantsPlasmidsProcessProtein BiosynthesisProtein Synthesis InhibitionProteinsRNA SplicingResistanceRespiratory SystemRibosomal RNARibosomesRicinRicinus communisRiskRoleSignal PathwaySignal TransductionSmall Interfering RNASystemTechniquesTerrorismToxinTranslationsVaccinesYeastsbasebiodefensecell injurycell killingcytotoxicitydesigninstrumentmutantnovel therapeuticspreventprototyperesponseribosomal A-protein
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
001912864
UEI
M1LVPE5GLSD9
Project Start Date
15-March-2007
Project End Date
29-February-2012
Budget Start Date
15-March-2007
Budget End Date
29-February-2008
Project Funding Information for 2007
Total Funding
$353,234
Direct Costs
$250,000
Indirect Costs
$103,234
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Allergy and Infectious Diseases
$353,234
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AI072425-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AI072425-01A1
Patents
No Patents information available for 1R01AI072425-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AI072425-01A1
Clinical Studies
No Clinical Studies information available for 1R01AI072425-01A1
News and More
Related News Releases
No news release information available for 1R01AI072425-01A1
History
No Historical information available for 1R01AI072425-01A1
Similar Projects
No Similar Projects information available for 1R01AI072425-01A1